ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

New Chemotherapy, Other Modality Progress Described

March 30, 1979

Alcohol Consumption Increases Risk Of Lobular And HR+ Breast Cancer

August 27, 2010

An Appreciation: Eddie Reed, 60, a Developer of Taxol

June 6, 2014

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

October 25, 1985

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012

In Brief: House Cuts NCI Rescission To $7.73 Million; Weinhuse, Ultmann New ACCR, ASCO Presidents

May 8, 1981